Two doses of psilocybin (20 and 30 mg per 70 kg) combined with supportive psychotherapy produced large, rapid antidepressant effects in adults with major depressive disorder who were not taking other antidepressants. In a randomized waiting list-controlled trial with 24 completers, depression scores on the GRID-Hamilton scale dropped from a mean of 22.8 at baseline to 8.0 one week after the second session, compared with 23.8 at the same time point in the delayed-treatment group. Seventy-one percent of participants showed a clinically significant response at week 1, and 58% met remission criteria. Effects persisted through the four-week follow-up.
Chronic pain and functional disabilities can transform a person's identity and sense of meaning. Existing treatments often fail to provide adequate pain relief or functional recovery, and psychological issues like depression, anxiety, and fear of movement can worsen outcomes by reducing engagement in rehabilitation. Psilocybin alters consciousness by changing connectivity in brain regions involved in self-perception and movement. Early evidence suggests it helps with psychiatric disorders and unhelpful coping, but its potential for pain relief and improving rehabilitation participation through changes in self-perception and meaning-making is underexplored. This article proposes using psilocybin as a psychophysical adaptogen to reframe perceived barriers to exercise and improve both illness identity and neuromotor outcomes.